DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway

Cell Communication and Signaling

Volumn 15, Issue 1, 2017, Pages

  Bhattacharjee, Sonali ^a   Nandi, Saikat ^a  

^a Simons Center for Quantitative Biology   (United States)

Author keywords

Cancer therapeutics; Combination Therapy Genomic instability; DNA damage response; DNA repair; Fanconi Anemia (FA) signaling network; Homologous recombination; Interstrand crosslink (ICL); Synthetic lethality; Translesion synthesis

Indexed keywords

2 [4 [2 [3 CYCLOHEXYL 1 (4 CYCLOHEXYLBUTYL)UREIDO]ETHYL]PHENYLTHIO] 2 METHYLPROPIONIC ACID; 3,5 BIS(2 FLUOROBENZYLIDENE) 4 PIPERIDINONE; 4 PHENYLBUTYRIC ACID; ALSTERPAULLONE; BORTEZOMIB; BRCA1 PROTEIN; BRCA2 PROTEIN; C 527; CISPLATIN; CURCUMIN; DNA; DNA LIGASE; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP D2 PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; FANCONI ANEMIA GROUP I PROTEIN; FANCONI ANEMIA GROUP L PROTEIN; FANCONI ANEMIA GROUP N PROTEIN; FANCONI ANEMIA PROTEIN; HETERODIMER; N (2 AMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NUCLEAR PROTEIN; PEVONEDISTAT; PIMOZIDE; UNCLASSIFIED DRUG; WORTMANNIN;

BREAST CANCER; CARCINOGENESIS; CHEMOSENSITIZATION; DISEASE ASSOCIATION; DNA CROSS LINKING; DNA DAMAGE RESPONSE; DNA REPAIR; DRUG DESIGN; DRUG TARGETING; ENZYME INHIBITION; EXCISION REPAIR; FANCONI ANEMIA; GENE MUTATION; GENOMIC INSTABILITY; HEAD AND NECK CANCER; HOMOLOGOUS RECOMBINATION; HUMAN; LEUKEMIA; LUNG CANCER; MALIGNANT NEOPLASM; MISMATCH REPAIR; OVARY CANCER; PANCREAS CANCER; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE STRANDED DNA BREAK; STOMACH CANCER; UBIQUITINATION; DNA DAMAGE; GENETICS; NEOPLASM; PATHOLOGY;

DNA DAMAGE; DNA REPAIR; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 85031099180     PISSN: None     EISSN: 1478811X     Source Type: Journal    
DOI: 10.1186/s12964-017-0195-9     Document Type: Review

References (144)

1. Mathew CG. Fanconi anaemia genes and susceptibility to cancer. Oncogene. 2006;25(43):5875-84.
2. Meetei AR, et al. X-linked inheritance of Fanconi anemia complementation group B. Nat Genet. 2004;36(11):1219-24.
3. Su XY, Huang J. The Fanconi anemia pathway and DNA interstrand cross-link repair. Protein Cell. 2011;2(9):704-11.
4. Alter BP. Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol. 2014;27(3-4):214-21.
5. Rosenberg PS, Tamary H, Alter BP. How high are carrier frequencies of rare recessive syndromes? Contemporary estimates for Fanconi Anemia in the United States and Israel. Am J Med Genet A. 2011;155A(8):1877-83.
6. Garaycoechea JI, et al. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature. 2012;489(7417):571-5.
7. Ceccaldi R, et al. Bone marrow failure in Fanconi Anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell. 2012;11(1):36-49.
8. Lobitz S, Velleuer E. Guido Fanconi (1892-1979): a jack of all trades. Nat Rev Cancer. 2006;6(11):893-8.
9. Schroeder TM, Kurth R. Spontaneous chromosomal breakage and high incidence of leukemia in inherited disease. Blood. 1971;37(1):96-112.
10. German J. Genes which increase chromosomal instability in somatic cells and predispose to cancer. Prog Med Gen. 1972;8:61.
11. Moldovan GL, D'Andrea AD. How the fanconi anemia pathway guards the genome. Annu Rev Genet. 2009;43:223-49.
12. Niedernhofer LJ, Lalai AS, Hoeijmakers JH. Fanconi anemia (cross)linked to DNA repair. Cell. 2005;123(7):1191-8.
13. Patel KJ, Joenje H. Fanconi anemia and DNA replication repair. DNA Repair (Amst). 2007;6(7):885-90.
14. Thompson LH, Hinz JM. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: mechanistic insights. Mutat Res. 2009;668(1-2):54-72.
15. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet. 2007;8(10):735-48.
16. Jung Y, Lippard SJ. Direct cellular responses to platinum-induced DNA damage. Chem Rev. 2007;107(5):1387-407.
17. Taniguchi T, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003;9(5):568-74.
18. Landais I, et al. A novel cell-free screen identifies a potent inhibitor of the Fanconi anemia pathway. Int J Cancer. 2009;124(4):783-92.
19. Vogel EW, et al. Heritable and cancer risks of exposures to anticancer drugs: inter-species comparisons of covalent deoxyribonucleic acid-binding agents. Mutat Res. 1998;400(1-2):509-40.
20. Stern RS. Psoralen and ultraviolet a light therapy for psoriasis. N Engl J Med. 2007;357(7):682-90.
21. Clauson C, Scharer OD, Niedernhofer L. Advances in understanding the complex mechanisms of DNA interstrand cross-link repair. Cold Spring Harb Perspect Biol. 2013;5(10):a012732.
22. McHugh PJ, Spanswick VJ, Hartley JA. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2001;2(8):483-90.
23. Nojima K, et al. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res. 2005;65(24):11704-11.
24. Ben-Yehoyada M, et al. Checkpoint signaling from a single DNA interstrand crosslink. Mol Cell. 2009;35(5):704-15.
25. Thompson LH, et al. How Fanconi anemia proteins promote the four Rs: replication, recombination, repair, and recovery. Environ Mol Mutagen. 2005;45(2-3):128-42.
26. Akkari YM, et al. DNA replication is required to elicit cellular responses to Psoralen-induced DNA Interstrand cross-links. Mol Cell Biol. 2000;20(21):8283-9.
27. Raschle M, et al. Mechanism of replication-coupled DNA interstrand crosslink repair. Cell. 2008;134(6):969-80.
28. Zhu W, Abbas T, Dutta A. DNA replication and genomic instability. Adv Exp Med Biol. 2005;570:249-79.
29. Sclafani RA, Holzen TM. Cell cycle regulation of DNA replication. Annu Rev Genet. 2007;41:237-80.
30. Fu YV, et al. Selective bypass of a lagging strand roadblock by the eukaryotic replicative DNA helicase. Cell. 2011;146(6):931-41.
31. Long DT, et al. BRCA1 promotes unloading of the CMG helicase from a stalled DNA replication fork. Mol Cell. 2014;56(1):174-85.
32. Knipscheer P, et al. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science. 2009;326(5960):1698-701.
33. Ciccia A, McDonald N, West SC. Structural and functional relationships of the XPF/MUS81 family of proteins. Annu Rev Biochem. 2008;77:259-87.
34. Sengerova B, Wang AT, McHugh PJ. Orchestrating the nucleases involved in DNA interstrand cross-link (ICL) repair. Cell Cycle. 2011;10(23):3999-4008.
35. Yamamoto KN, et al. Involvement of SLX4 in interstrand cross-link repair is regulated by the Fanconi anemia pathway. Proc Natl Acad Sci U S A. 2011;108(16):6492-6.
36. Crossan GP, et al. Disruption of mouse Slx4, a regulator of structure-specific nucleases, phenocopies Fanconi anemia. Nat Genet. 2011;43(2):147-U99.
37. Hodskinson MRG, et al. Mouse SLX4 is a tumor suppressor that stimulates the activity of the nuclease XPF-ERCC1 in DNA crosslink repair. Mol Cell. 2014;54(3):472-84.
38. Douwel DK, et al. XPF-ERCC1 acts in unhooking DNA Interstrand Crosslinks in cooperation with FANCD2 and FANCP/SLX4. Mol Cell. 2014;54(3):460-71.
39. Guervilly JH, et al. The SLX4 complex is a SUMO E3 Ligase that impacts on replication stress outcome and genome stability. Mol Cell. 2015;57(1):123-37.
40. Liu T, et al. FAN1 acts with FANCI-FANCD2 to promote DNA Interstrand cross-link repair. Science. 2010;329(5992):693-6.
41. Smogorzewska A, et al. A genetic screen identifies FAN1, a Fanconi Anemia-associated nuclease necessary for DNA Interstrand crosslink repair. Mol Cell. 2010;39(1):36-47.
42. Zhao Q, et al. Structural insights into 5 ' flap DNA unwinding and incision by the human FAN1 dimer. Nat Commun. 2014;5:5726.
43. Takahashi D, et al. Human FAN1 promotes strand incision in 5 '-flapped DNA complexed with RPA. J Biochem. 2015;158(3):263-70.
44. Pizzolato J, et al. FANCD2-associated nuclease 1, but not exonuclease 1 or flap Endonuclease 1, is able to unhook DNA Interstrand cross-links in vitro. J Biol Chem. 2015;290(37):22602-11.
45. Mirchandani KD, D'Andrea AD. The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair. Exp Cell Res. 2006;312(14):2647-53.
46. Prakash S, Johnson RE, Prakash L. Eukaryotic translesion synthesis DNA polymerases: specificity of structure and function. Annu Rev Biochem. 2005;74:317-53.
47. Long DT, et al. Mechanism of RAD51-dependent DNA interstrand cross-link repair. Science. 2011;333(6038):84-7.
48. Bhattacharjee S, Nandi S. Choices have consequences: the nexus between DNA repair pathways and genomic instability in cancer. Clin Transl Med. 2016;5(1):45.
49. Kee Y, D'Andrea AD. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 2010;24(16):1680-94.
50. Wang LC, Gautier J. The Fanconi anemia pathway and ICL repair: implications for cancer therapy. Crit Rev Biochem Mol Biol. 2010;45(5):424-39.
51. Sun W, et al. The FANCM Ortholog Fml1 promotes recombination at stalled replication forks and limits crossing over during DNA double-strand break repair. Mol Cell. 2008;32(1):118-28.
52. Nandi S, Whitby MC. The ATPase activity of Fml1 is essential for its roles in homologous recombination and DNA repair. Nucleic Acids Res. 2012;40(19):9584-95.
53. Bhattacharjee S, et al. MHF1-2/CENP-S-X performs distinct roles in centromere metabolism and genetic recombination. Open Biology. 2013:3(9):130102.
54. Dong HB, et al. Update of the human and mouse Fanconi anemia genes. Human Genomics. 2015;9:32.
55. Chen H, Zhang S, Wu Z. Fanconi anemia pathway defects in inherited and sporadic cancers. Transl Pediatr. 2014;3(4):300-4.
56. Ciccia A, et al. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. Mol Cell. 2007;25(3):331-43.
57. Ling C, et al. FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. EMBO J. 2007;26(8):2104-14.
58. Ali AM, et al. FAAP20: a novel ubiquitin-binding FA nuclear core-complex protein required for functional integrity of the FA-BRCA DNA repair pathway. Blood. 2012;119(14):3285-94.
59. Kim H, et al. Regulation of Rev1 by the Fanconi anemia core complex. Nat Struct Mol Biol. 2012;19(2):164-70.
60. Ceccaldi R, Sarangi P, D'Andrea AD. The Fanconi anaemia pathway: new players and new functions. Nat Rev Mol Cell Biol. 2016;17(6):337-49.
61. Cheung RS, et al. Ubiquitination-linked Phosphorylation of the FANCI S/TQ cluster contributes to activation of the Fanconi anemia I/D2 complex. Cell Rep. 2017;19(12):2432-40.
62. de Oca RM, et al. Regulated interaction of the Fanconi anemia protein, FANCD2, with chromatin. Blood. 2005;105(3):1003-9.
63. Dorsman JC, et al. Identification of the Fanconi anemia complementation group I gene. FANCI Cell Oncol. 2007;29(3):211-8.
64. Smogorzewska A, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell. 2007;129(2):289-301.
65. Duxin JP, Walter JC. What is the DNA repair defect underlying Fanconi anemia? Curr Opin Cell Biol. 2015;37:49-60.
66. Mamrak NE, Shimamura A, Howlett NG. Recent discoveries in the molecular pathogenesis of the inherited bone marrow failure syndrome Fanconi anemia. Blood Rev. 2017;31(3):93-9.
67. Kim JM, et al. Cell cycle-dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24. Blood. 2008;111(10):5215-22.
68. Singh TR, et al. MHF1-MHF2, a histone-fold-containing protein complex, participates in the Fanconi anemia pathway via FANCM. Mol Cell. 2010;37(6):879-86.
69. Yan Z, et al. A histone-fold complex and FANCM form a conserved DNA-remodeling complex to maintain genome stability. Mol Cell. 2010;37(6):865-78.
70. Ling C, et al. Bloom syndrome complex promotes FANCM recruitment to stalled replication forks and facilitates both repair and traverse of DNA interstrand crosslinks. Cell Discov. 2016;2:16047.
71. Kennedy RD, D'andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev. 2005;19(24):2925-40.
72. Ho GPH, et al. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol. 2006;26(18):7005-15.
73. Ishiai M, et al. FANCI phosphorylation functions as a molecular switch to turn on the Fanconi anemia pathway. Nat Struct Mol Biol. 2008;15(11):1138-46.
74. Hira A, et al. Mutations in the gene encoding the E2 conjugating enzyme UBE2T cause Fanconi anemia. Am J Hum Genet. 2015;96(6):1001-7.
75. Miles JA, et al. The Fanconi Anemia DNA repair pathway is regulated by an interaction between Ubiquitin and the E2-like fold domain of FANCL. J Biol Chem. 2015;290(34):20995-1006.
76. Rickman KA, et al. Deficiency of UBE2T, the E2 Ubiquitin Ligase necessary for FANCD2 and FANCI Ubiquitination, causes FA-T subtype of Fanconi anemia. Cell Rep. 2015;12(1):35-41.
77. Virts EL, et al. AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of Fanconi anemia. Hum Mol Genet. 2015;24(18):5093-108.
78. Howlett NG, et al. Functional interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a conserved putative PCNA interaction motif. J Biol Chem. 2009;284(42):28935-42.
79. Geng LY, Huntoon CJ, Karnitz LM. RAD18-mediated ubiquitination of PCNA activates the Fanconi anemia DNA repair network. J Cell Biol. 2010;191(2):249-57.
80. Williams SA, et al. The E3 ubiquitin ligase RAD18 regulates ubiquitylation and chromatin loading of FANCD2 and FANCI. Blood. 2011;117(19):5078-87.
81. Liang CC, et al. UHRF1 is a sensor for DNA Interstrand Crosslinks and recruits FANCD2 to initiate the Fanconi Anemia pathway. Cell Rep. 2015;10(12):1947-56.
82. Tian YY, et al. UHRF1 contributes to DNA damage repair as a lesion recognition factor and nuclease scaffold. Cell Rep. 2015;10(12):1957-66.
83. Nijman SMB, et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell. 2005;17(3):331-9.
84. Oestergaard VH, et al. Deubiquitination of FANCD2 is required for DNA crosslink repair. Mol Cell. 2007;28(5):798-809.
85. Kim JM, et al. Inactivation of Murine Usp1 results in genomic instability and a Fanconi Anemia phenotype. Dev Cell. 2009;16(2):314-20.
86. Cohn MA, et al. A UAF1-containing multisubunit protein complex regulates the Fanconi anemia pathway. Mol Cell. 2007;28(5):786-97.
87. Kim Y, et al. Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4. Blood. 2013;121(1):54-63.
88. Klein Douwel D, et al. XPF-ERCC1 acts in unhooking DNA interstrand crosslinks in cooperation with FANCD2 and FANCP/SLX4. Mol Cell. 2014;54(3):460-71.
89. Svendsen JM, et al. Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair. Cell. 2009;138(1):63-77.
90. Munoz IM, et al. Coordination of structure-specific nucleases by human SLX4/BTBD12 is required for DNA repair. Mol Cell. 2009;35(1):116-27.
91. Zhang J, Walter JC. Mechanism and regulation of incisions during DNA interstrand cross-link repair. DNA Repair (Amst). 2014;19:135-42.
92. Lambert MW. Nuclear alpha spectrin: critical roles in DNA interstrand cross-link repair and genomic stability. Exp Biol Med (Maywood). 2016;241(15):1621-38.
93. McMahon LW, et al. Human alpha spectrin II and the FANCA, FANCC, and FANCG proteins bind to DNA containing psoralen interstrand cross-links. Biochemistry. 2001;40(24):7025-34.
94. Sridharan D. Nonerythroid alphaII spectrin is required for recruitment of FANCA and XPF to nuclear foci induced by DNA interstrand cross-links. J Cell Sci. 2003;116(5):823-35.
95. Waters LS, et al. Eukaryotic Translesion polymerases and their roles and regulation in DNA damage tolerance. Microbiol Mol Biol Rev. 2009;73(1):134.
96. de Groote FH, et al. The Rev1 translesion synthesis polymerase has multiple distinct DNA binding modes. DNA Repair. 2011;10(9):915-25.
97. Vaz F, et al. Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010;42(5):406-9.
98. Prakash R, et al. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol. 2015;7(4):a016600.
99. Yang H, et al. The BRCA2 homologue Brh2 nucleates RAD51 filament formation at a dsDNA-ssDNA junction. Nature. 2005;433(7026):653-7.
100. Somyajit K, Subramanya S, Nagaraju G. RAD51C: a novel cancer susceptibility gene is linked to Fanconi anemia and breast cancer. Carcinogenesis. 2010;31(12):2031-8.
101. Zhong Q, et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science. 1999;285(5428):747-50.
102. Yu X, et al. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J Biol Chem. 1998;273(39):25388-92.
103. Wong AK, et al. Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene. 1998;17(18):2279-85.
104. Sartori AA, et al. Human CtIP promotes DNA end resection. Nature. 2007;450(7169):509-14.
105. Bunting SF, Nussenzweig A. Dangerous liaisons: Fanconi anemia and toxic nonhomologous end joining in DNA crosslink repair. Mol Cell. 2010;39(2):164-6.
106. Gupta R, et al. Analysis of the DNA substrate specificity of the human BACH1 helicase associated with breast cancer. J Biol Chem. 2005;280(27):25450-60.
107. Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev. 2004;18(16):1958-63.
108. Pichierri P, Rosselli F. The DNA crosslink-induced S-phase checkpoint depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. EMBO J. 2004;23(5):1178-87.
109. Collins NB, et al. ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. Blood. 2009;113(10):2181-90.
110. Qiao FY, et al. Phosphorylation of Fanconi anemia (FA) complementation group G protein, FANCG, at serine 7 is important for function of the FA pathway. J Biol Chem. 2004;279(44):46035-45.
111. Wilson JB, et al. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. Oncogene. 2008;27(26):3641-52.
112. Xia B, et al. Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet. 2007;39(2):159-61.
113. Kee Y, Kim JM, D'Andrea A. Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis. Genes Dev. 2009;23(5):555-60.
114. Wang XZ, et al. Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell Biol. 2007;27(8):3098-108.
115. Meetei AR, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet. 2003;35(2):165-70.
116. Machida YJ, et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell. 2006;23(4):589-96.
117. Orthwein A, et al. A mechanism for the suppression of homologous recombination in G1 cells. Nature. 2015;528(7582):422.
118. Zhu B, et al. K63-linked ubiquitination of FANCG is required for its association with the Rap80-BRCA1 complex to modulate homologous recombination repair of DNA interstand crosslinks. Oncogene. 2015;34(22):2867-78.
119. Gibbs-Seymour I, et al. Ubiquitin-SUMO circuitry controls activated Fanconi Anemia ID complex dosage in response to DNA damage. Mol Cell. 2015;57(1):150-64.
120. He HJ, et al. DNA replication components as regulators of epigenetic inheritance-lesson from fission yeast centromere. Protein Cell. 2014;5(6):411-9.
121. Kutler DI, et al. A 20-year perspective on the international Fanconi Anemia registry (IFAR). Blood. 2003;101(4):1249-56.
122. Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.pdf. MedGenMed. 2005;29;7(2):60.
123. van der Heijden MS, et al. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res. 2003;63(10):2585-8.
124. Hess CJ, et al. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. Cell Oncol. 2008;30(4):299-306.
125. Barroso E, et al. FANCD2 associated with sporadic breast cancer risk. Carcinogenesis. 2006;27(9):1930-7.
126. Erkko H, et al. A recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007;446(7133):316-9.
127. Couch FJ, et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res. 2005;65(2):383-6.
128. Rogers CD, et al. The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol Ther. 2004;3(2):167-9.
129. Helleday T, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8(3):193-204.
130. Jenkins C, Kan J, Hoatlin ME. Targeting the fanconi anemia pathway to identify tailored anticancer therapeutics. Anemia. 2012;2012:481583.
131. Bryant HE, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913-7.
132. Farmer H, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917-21.
133. Malyuchenko NV, et al. PARP1 Inhibitors: antitumor drug design. Acta Nat. 2015;7(3):27-37.
134. Johnson N, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med. 2011;17(7):875-82.
135. Kennedy RD, et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Investig. 2007;117(5):1440-9.
136. Fang NY, et al. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma. Proc Natl Acad Sci U S A. 2003;100(9):5372-7.
137. Haidar MA, et al. ATM gene deletion in patients with adult acute lymphoblastic leukemia. Cancer. 2000;88(5):1057-62.
138. Chen CC, et al. CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors. Mol Cancer. 2009;8:24.
139. Chirnomas D, et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol Cancer Ther. 2006;5(4):952-61.
140. Burkitt K, Ljungman M. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin. Mol Cancer. 2008;7:24.
141. Kee Y, et al. Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents. Mol Cancer Res. 2012;10(3):369-77.
142. Chen J, et al. Selective and cell-active inhibitors of the USP1/ UAF1 deubiquitinase complex reverse cisplatin resistance in non-small cell lung cancer cells. Chem Biol. 2011;18(11):1390-400.
143. Liang Q, et al. A selective USP1-UAF1 inhibitor links deubiquitination to DNA damage responses. Nat Chem Biol. 2014;10(4):298-304.
144. Mistry H, et al. Small-molecule inhibitors of USP1 target ID1 degradation in leukemic cells. Mol Cancer Ther. 2013;12(12):2651-62.